The mTOR inhibitor Sapanisertib is a putative longevity molecule that makes human skin cells & prematurely old fish healthier

RapAdmin · 2025-03-01T21:49:23.659Z

Taken together, our study introduces a unique and efficient model for large-scale antiaging drug screening in vertebrates and suggests sapanisertib as a potential therapeutic option for treating premature aging and promoting healthy aging.

Paywalled paper:

Establishment and application of a zebrafish model of Werner syndrome identifies sapanisertib as a potential antiaging drug

https://www.pnas.org/doi/10.1073/pnas.2413719122

en.wikipedia.org

Sapanisertib

Sapanisertib (also known as MLN0128, INK128 and TAK-228) is an experimental small molecule inhibitor of mTOR which is administered orally. It targets both mTORC1 and mTORC2. Developed by Millennium Pharmaceuticals, and is in phase II clinical trials for breast cancer, endometrial cancer, glioblastoma, renal cell carcinoma, and thyroid cancer. The drug has been well tolerated by patients with advanced solid tumours in Phase I trials.

Screen Shot 2025-03-01 at 1.46.34 PM984×1290 83.1 KB

Source: https://x.com/davidasinclair/status/1895939773455614448

Screen Shot 2025-03-01 at 1.47.07 PM982×1328 89.4 KB

Screen Shot 2025-03-01 at 1.47.56 PM1008×1328 102 KB

Screen Shot 2025-03-01 at 1.48.30 PM994×1212 109 KB

https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-300/subpart-B/section-300.50

RapAdmin · 2025-03-01T23:22:23.985Z

But - then here is some new input from Dudley Lamming, who is much more an MTOR expert (having worked in David Sabatini’s lab as a PostDoc) than David Sinclair:

Screen Shot 2025-03-01 at 3.20.36 PM972×474 50.9 KB

Source: https://x.com/LammingLab/status/1895968197867885006